News Quantified

CRIS – curis, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Curis, Inc. (NASDAQ: CRIS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $26.00 price target on the stock.

Curis Provides First Quarter 2024 Business Update [Yahoo! Finance]

Curis Provides First Quarter 2024 Business Update

Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024 [Yahoo! Finance]

Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024

0.2%

MISS

10.7%

MISS

-10.7%

BEAT

-8.8%

IN-LINE

Form 10-Q CURIS INC For: Mar 31

Form 8-K CURIS INC For: May 07

Form SC 13G CURIS INC Filed by: KINGDON CAPITAL MANAGEMENT, L.L.C.

Form EFFECT CURIS INC

Form ARS CURIS INC For: Dec 31

Top News Gainers

4/27 Form 8-K CURIS INC For: Apr 21 12.4%

2/27 Form 8-K CURIS INC For: Feb 26 11.8%

11/20 Curis, Inc. (NASDAQ: CRIS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 10.1%

12/6 Form 8-K CURIS INC For: Dec 06 8.6%

11/26 Curis to Present at 31st Annual Piper Jaffray Healthcare Conference 7.3%

10/29 Curis to Release Third Quarter Financial Results and Hold Conference Call on November 5, 2019 7.0%

8/13 Curis Hires Industry Veterans to Lead Clinical Development and Regulatory Affairs 4.9%

9/12 Form 4 CURIS INC For: Sep 10 Filed by: Steinkrauss William 3.5%

2/6 Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170 3.4%

10/4 Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 3.2%

Top News Decliners

8/6 Q2/2019 6/30/2019 EPS -0.220 ZacksConsensus N/A ActVsEst N/A - N/A -22.0%

12/6 Curis Provides First-Ever Demonstration that Targeting IRAK4 in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Results in Anti-Cancer Activity in Ongoing Phase 1 Study -21.1%

11/5 Q3/2019 9/30/2019 EPS -0.190 ZacksConsensus N/A ActVsEst N/A - N/A -18.8%

3/14 Curis, Inc. (NASDAQ: CRIS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -15.9%

1/7 Curis Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies -12.2%

11/5 Curis Inc.'s (CRIS) CEO James Dentzer on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] -9.6%

3/19 Curis Inc.'s (CRIS) CEO James Dentzer on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -9.3%

4/7 Curis to Present at 19th Annual Needham Virtual Healthcare Conference -8.8%

3/6 Form 8-K CURIS INC For: Mar 04 -8.3%

3/12 Curis to Release Fourth Quarter and Year-End 2019 Financial Results and Hold Conference Call on March 19, 2020 -7.3%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day